Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials.

HBV-positive patients showed a trend in favor of sorafenib rather than placebo for TTP (HR 0.74 CI 95% 0.48–1.14 p = 0.18) and OS (HR 0.74 CI 95% 0.544-1.03 p = 0.08) ( Figure 1C and Figure 1D ).

also in 53,322 other papers

In the overall population no difference was observed between lenvatinib and sorafenib, despite if a slight trend toward a greater efficacy of lenvatinib (HR 0.92, 95% CrI 0.61–1.36) ( Figure 2A ).

also in 4,078 other papers

Results: For HBV-positive patients, there was a clear trend in favor of lenvatinib over sorafenib (HR 0.82 95% credible interval [CrI] 0.60–1.15).

also in 19,460 other papers